Patents by Inventor Angel Francisco Lopez
Angel Francisco Lopez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230416381Abstract: The present disclosure relates to methods of treating or preventing acute respiratory distress syndrome (ARDS) using compounds that bind to CD131 and neutralize signaling by IL-3, IL-5 and GM-CSF. The present disclosure also relates to compounds for use in the treatment or prevention of ARDS, as well as the use of such compounds in the manufacture of medicaments for the treatment or prevention of ARDS.Type: ApplicationFiled: December 20, 2021Publication date: December 28, 2023Inventors: Catherine Mary OWCZAREK, Ian Keith CAMPBELL, Karolina KRSTEVSKI, Steven BOZINOVSKI, Angel Francisco LOPEZ, Damon John TUMES
-
Publication number: 20230406943Abstract: The present disclosure relates to methods of treating inflammatory skin conditions using compounds that bind to CD131 and inhibit GM-CSF and IL-5 signaling. The present disclosure also relates to compounds for use in the treatment or prevention of an inflammatory skin condition, as well as the use of such compounds in the manufacture of medicaments for the treatment or prevention of inflammatory skin conditions.Type: ApplicationFiled: December 3, 2021Publication date: December 21, 2023Inventors: Catherine Mary OWCZAREK, Angel Francisco LOPEZ, Ho Kwok YIP, Damon John TUMES
-
Publication number: 20220251659Abstract: The present invention provides a method of screening a mammal for the onset or predisposition to the onset of a neuropsychiatric disorder. More particularly, the present invention provides a method of screening a mammal for the onset or predisposition to the onset of schizophrenia by screening for a decrease in the functional level of protein 1 4-3-3?. In a related aspect, the present invention also provides a means of monitoring a patient diagnosed with a neuropsychiatric disorder, such as schizophrenia, by screening for changes to functional levels of protein 14-3-3 ?. This may be useful, for example, in the context of evaluating the effectiveness of a prophylactic or therapeutic treatment regime or otherwise monitoring the impact of physiological or metabolic changes which may occur in a patient.Type: ApplicationFiled: February 2, 2022Publication date: August 11, 2022Inventors: Quenten Philip Schwarz, Angel Francisco Lopez
-
Patent number: 11274346Abstract: The present invention provides a method of screening a mammal for the onset or predisposition to the onset of a neuropsychiatric disorder. More particularly, the present invention provides a method of screening a mammal for the onset or predisposition to the onset of schizophrenia by screening for a decrease in the functional level of protein 14-3-3?. In a related aspect, the present invention also provides a means of monitoring a patient diagnosed with a neuropsychiatric disorder, such as schizophrenia, by screening for changes to functional levels of protein 14-3-3?. This may be useful, for example, in the context of evaluating the effectiveness of a prophylactic or therapeutic treatment regime or otherwise monitoring the impact of physiological or metabolic changes which may occur in a patient.Type: GrantFiled: October 21, 2019Date of Patent: March 15, 2022Assignee: PRECISION MEDICINE HOLDINGS PTY LTDInventors: Quenten Philip Schwarz, Angel Francisco Lopez
-
Publication number: 20210292424Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: March 18, 2021Publication date: September 23, 2021Applicant: CSL LIMITEDInventors: Devendra Keshaorao HIWASE, Timothy Peter HUGHES, Angel Francisco LOPEZ, Gino Luigi VAIRO
-
Publication number: 20200277389Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: September 24, 2019Publication date: September 3, 2020Applicant: CSL LIMITEDInventors: Devendra Keshaorao HIWASE, Timothy Peter HUGHES, Angel Francisco LOPEZ, Gino Luigi VAIRO
-
Publication number: 20200102615Abstract: The present invention provides a method of screening a mammal for the onset or predisposition to the onset of a neuropsychiatric disorder. More particularly, the present invention provides a method of screening a mammal for the onset or predisposition to the onset of schizophrenia by screening for a decrease in the functional level of protein 14-3-3?. In a related aspect, the present invention also provides a means of monitoring a patient diagnosed with a neuropsychiatric disorder, such as schizophrenia, by screening for changes to functional levels of protein 14-3-3?. This may be useful, for example, in the context of evaluating the effectiveness of a prophylactic or therapeutic treatment regime or otherwise monitoring the impact of physiological or metabolic changes which may occur in a patient.Type: ApplicationFiled: October 21, 2019Publication date: April 2, 2020Inventors: Quenten Philip Schwarz, Angel Francisco Lopez
-
Patent number: 10494674Abstract: The present invention provides a method of screening a mammal for the onset or predisposition to the onset of a neuropsychiatric disorder. More particularly, the present invention provides a method of screening a mammal for the onset or predisposition to the onset of schizophrenia by screening for a decrease in the functional level of protein 1 4-3-3?. In a related aspect, the present invention also provides a means of monitoring a patient diagnosed with a neuropsychiatric disorder, such as schizophrenia, by screening for changes to functional levels of protein 14-3-3 ?. This may be useful, for example, in the context of evaluating the effectiveness of a prophylactic or therapeutic treatment regime or otherwise monitoring the impact of physiological or metabolic changes which may occur in a patient.Type: GrantFiled: March 19, 2018Date of Patent: December 3, 2019Assignee: PRECISION MEDICINE HOLDINGS PTY LTDInventors: Quenten Philip Schwarz, Angel Francisco Lopez
-
Publication number: 20190062837Abstract: The present invention provides a method of screening a mammal for the onset or predisposition to the onset of a neuropsychiatric disorder. More particularly, the present invention provides a method of screening a mammal for the onset or predisposition to the onset of schizophrenia by screening for a decrease in the functional level of protein 1 4-3-3?. In a related aspect, the present invention also provides a means of monitoring a patient diagnosed with a neuropsychiatric disorder, such as schizophrenia, by screening for changes to functional levels of protein 14-3-3 ?. This may be useful, for example, in the context of evaluating the effectiveness of a prophylactic or therapeutic treatment regime or otherwise monitoring the impact of physiological or metabolic changes which may occur in a patient.Type: ApplicationFiled: March 19, 2018Publication date: February 28, 2019Inventors: Quenten Philip Schwarz, Angel Francisco Lopez
-
Publication number: 20180244786Abstract: The present disclosure provides antibodies and antigen binding fragments thereof that bind to an epitope within an interleukin-3 receptor ?.Type: ApplicationFiled: October 3, 2017Publication date: August 30, 2018Inventors: Angel Francisco LOPEZ, Timothy Robert HERCUS, Sophie Elizabeth BROUGHTON, Michael William PARKER, Nicholas WILSON, Matthew HARDY
-
Patent number: 9920371Abstract: The present invention provides a method of screening a mammal for the onset or predisposition to the onset of a neuropsychiatric disorder. More particularly, the present invention provides a method of screening a mammal for the onset or predisposition to the onset of schizophrenia by screening for a decrease in the functional level of protein 14-3-3?. In a related aspect, the present invention also provides a means of monitoring a patient diagnosed with a neuropsychiatric disorder, such as schizophrenia, by screening for changes to functional levels of protein 14-3-3?. This may be useful, for example, in the context of evaluating the effectiveness of a prophylactic or therapeutic treatment regime or otherwise monitoring the impact of physiological or metabolic changes which may occur in a patient.Type: GrantFiled: September 21, 2012Date of Patent: March 20, 2018Assignee: Medvet Sciences Pty. Ltd.Inventors: Quenten Philip Schwarz, Angel Francisco Lopez
-
Publication number: 20170362328Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: August 30, 2017Publication date: December 21, 2017Applicant: CSL LIMITEDInventors: Devendra Keshaorao HIWASE, Timothy Peter HUGHES, Angel Francisco LOPEZ, Gino Luigi VAIRO
-
Publication number: 20170218340Abstract: A method for producing a population of cells, enriched for non-adherent endothelial progenitor cells (EPCs), the method comprising culturing an EPC containing population of cells in the presence of interleukin-3 (IL-3), such that a population of cells enriched for non-adherent EPCs is produced.Type: ApplicationFiled: May 11, 2015Publication date: August 3, 2017Inventors: Claudine Sharon Bonder, Angel Francisco Lopez
-
Publication number: 20160304616Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: June 27, 2016Publication date: October 20, 2016Applicant: CSL LIMITEDInventors: Devendra Keshaorao Hiwase, Timothy Peter Hughes, Angel Francisco Lopez, Gino Luigi Vairo
-
Publication number: 20160053318Abstract: The present invention provides markers of endothelial progenitor cells (EPCs) and use of those markers and reagents that bind thereto to detect EPC cells or diagnose, prognose, treat or prevent EPC-associated conditions.Type: ApplicationFiled: September 4, 2015Publication date: February 25, 2016Applicant: Medvet Science Pty Ltd.Inventors: CLAUDINE SHARON BONDER, Angel Francisco Lopez, Gert Hoy Talbo
-
Publication number: 20160031996Abstract: The present disclosure provides antibodies and antigen binding fragments thereof that bind to an epitope within an interleukin-3 receptor ?.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Inventors: Angel Francisco LOPEZ, Timothy Robert HERCUS, Sophie Elizabeth BROUGHTON, Michael William PARKER, Nicholas WILSON, Matthew HARDY
-
Publication number: 20150093355Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: October 17, 2014Publication date: April 2, 2015Applicant: CSL LIMITEDInventors: Devendra Keshaorao HIWASE, Timothy Peter HUGHES, Angel Francisco LOPEZ, Gino Luigi VAIRO
-
Publication number: 20140237630Abstract: The present invention provides a method of screening a mammal for the onset or predisposition to the onset of a neuropsychiatric disorder. More particularly, the present invention provides a method of screening a mammal for the onset or predisposition to the onset of schizophrenia by screening for a decrease in the functional level of protein 14-3-3?. In a related aspect, the present invention also provides a means of monitoring a patient diagnosed with a neuropsychiatric disorder, such as schizophrenia, by screening for changes to functional levels of protein 14-3-3?. This may be useful, for example, in the context of evaluating the effectiveness of a prophylactic or therapeutic treatment regime or otherwise monitoring the impact of physiological or metabolic changes which may occur in a patient.Type: ApplicationFiled: September 21, 2012Publication date: August 21, 2014Applicant: Medvet Sciences Pty LtdInventors: Quenten Philip Schwarz, Angel Francisco Lopez
-
Patent number: 8489339Abstract: The present invention relates generally to the field of crystallography. More particularly, the present invention provides crystalline forms of a complex between granulocyte macrophage-colony stimulating factor (GM-CSF) and its receptor (GM-CSFR). The present invention further provides methods for the design and selection of modulators of GM-CSF/GM-CSFR interaction and signaling as well as signaling of other cytokines.Type: GrantFiled: November 1, 2007Date of Patent: July 16, 2013Assignees: St. Vincent's Institute of Medical Research, Central Adelaide Local Health NetworkInventors: Guido Hansen, Timothy Robert Hercus, Angel Francisco Lopez, William John McKinstry, Michael William Parker
-
Publication number: 20120244116Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: October 1, 2010Publication date: September 27, 2012Applicant: CSL LIMITEDInventors: Devendra Keshaorao Hiwase, Timothy Peter Hughes, Angel Francisco Lopez, Gino Luigi Vairo